Comparison of Long-Term Outcome in Anthracycline-Related Versus Idiopathic Dilated Cardiomyopathy: A Single Centre Experience
Key result
Anthracycline-induced cardiomyopathy was associated with a similar rate of the combined endpoint of death or heart transplantation compared to idiopathic dilated cardiomyopathy (25% vs 25%).
Why the study?
Does anthracycline-induced cardiomyopathy have worse long-term survival compared to idiopathic dilated cardiomyopathy?
Population
555 patients with heart failure, including 67 with anthracycline-induced cardiomyopathy and 488 with…
Comparison
Anthracycline-induced cardiomyopathy (AICM) vs Idiopathic dilated cardiomyopathy (IDCM)
Design
Cohort
Follow-up
7.6 ± 5.5 years (AICM) and 8.1 ± 5.5 years (IDCM)
Authors
Discussion
Loading...
Member takes
Implication
AICM survival matches IDCM; leaves open whether etiology-specific therapies alter outcomes in anthracycline cardiomyopathy.
Study Design
Type
Cohort (n=555)
Multicenter
No
Structured PICO
Does anthracycline-induced cardiomyopathy have worse long-term survival compared to idiopathic dilated cardiomyopathy?
P
Population
555 patients (67 with anthracycline-induced cardiomyopathy and 488 with idiopathic dilated cardiomyopathy) followed for a mean of approximately 8 years.
E
Exposure
Anthracycline-induced cardiomyopathy (AICM)
C
Comparator
Idiopathic dilated cardiomyopathy (IDCM)
O
Outcome
Combined endpoint of death or heart transplantationcomposite
Main Result
Absolute Event Rate: 25% vs 25%
Cardiovascular mortality in patients with anthracycline-induced cardiomyopathy is similar to that of idiopathic dilated cardiomyopathy, supporting the use of standard guideline-directed medical therapy for both.
Cite This Study
Fornaro et al. (2017) conducted a cohort in Anthracycline-induced cardiomyopathy (n=555). Anthracycline-induced cardiomyopathy vs. Idiopathic dilated cardiomyopathy was evaluated on combined endpoint of death/heart transplantation. Anthracycline-induced cardiomyopathy was associated with a similar rate of the combined endpoint of death or heart transplantation compared to idiopathic dilated cardiomyopathy (25% vs 25%).